君实生物:2024年盈利能力显著提升,但仍需关注现金流与债务状况

证券之星
29 Mar

近期君实生物(688180)发布2024年年报,证券之星财报模型分析如下:盈利能力显著提升君实生物(688180)在2024年实现了营业总收入19.48亿元,同比上升29.67%。归母净利润为-12.81亿元,同比上升43.90%,扣非净利润为-12.9亿元,同比上升43.86%。第四季度营业总收入为6.77亿元,同比上升31.2%,归母净利润为-3.54亿元,同比上升59.6%,扣非净利润为-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10